ERA Test in Patients With Recurrent Implantation Failure
Launched by IGENOMIX · Aug 16, 2012
Trial Information
Current as of August 23, 2025
Unknown status
Keywords
ClinConnect Summary
Intervention(s): Endometrial sampling, either at LH+7 in a natural cycle or after 5 days of progesterone in a hormonal replacement cycle (HRT) and personalized embryo transfer (pET) on the designated day guided by the ERA prediction.
Repeated implantation failure (RIF) is an unsolved not well characterized major cause of infertility in otherwise healthy women. Although various definitions of RIF exist, the clinical community agrees that after failure of three IVF cycles, in which one to two morphologically high-grade embryos have been transferred, special protocols must be enforced, althou...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women ≤38 years old
- • Normal ovarian reserve
- • FSH \<8mIU/mL
- • Cycle with ≥6 MII oocytes/oocyte retrieval
- • ≥3 implantation failures in previous IVF/ICSI cycles with transfer of atleast two good quality embryos in each cycle Inclusion Criteria for ovum donation recipients
- • ≥3 implantation failures with transfer of atleast two good quality embryos in each cycle
- • Endometrial thickness ≥ 6 mm
- • Trilaminar pattern after proper progesterone priming
- Exclusion Criteria:
- • Existance of hydrosalpinx
- • Atrophic endometrium \< 6 mm
- • Previous ectopic or uterine miscarriages
- • Presence of myomas or polyps
- • Previous embryo transfer with high difficulty and/or bleeding
About Igenomix
Igenomix is a leading global biotechnology company specializing in reproductive genetics and advanced genomic solutions. Committed to enhancing reproductive health, Igenomix provides innovative testing services that empower individuals and healthcare providers with critical information for informed decision-making in fertility treatments. With a strong emphasis on research and development, Igenomix leverages cutting-edge technologies to deliver accurate genetic assessments, facilitating personalized approaches to reproductive care. The company's dedication to excellence and patient-centric solutions positions it as a trusted partner in the field of reproductive medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, Vaencia, Spain
Patients applied
Trial Officials
Carlos Simón, MD PhD
Principal Investigator
ºIGENOMIX / IVI Valencia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials